In this On TRACK, I consider the stimulus provided by articles in the last issue of the Annals and the response of thoughtful readers commenting in the Annals online discussion (TRACK), and I provide my own interpretation. I encourage readers to write your own interpretation as an online comment to On TRACK or the original article.

PHARMACEUTICAL REP ADDICTION

The ethical analysis by Howard Brody provided a powerful stimulus for thoughtful and deeply felt replies. Dr. Brody argues that physicians ought to refuse to see pharmaceutical representatives (reps) on the grounds of both professional integrity and sensible time management.

Responses range from agreement to taking offense that “Dr. Brody must not practice in the real world.” Others suggest ways for physicians to manage, rather than avoid, the conflict, while one writer calls for a new code of conduct for education and practice, organizations, and individuals.

Picking up on an analogy in Dr. Brody’s analysis, John Scott labels the phenomenon as “Pharmaceutical Rep Addiction,” and prescribes a cure—abstinence.

One solo physician describes his own “recovery,” saving 1 to 2 hours each day and an office room, both of which allow him to spend more time seeing patients. He also describes a dramatic reduction in telephone calls from pharmacies as he began to prescribe fewer nonformulary drugs. A physician in group practice echoes the sentiment that eliminating free samples of the most expensive drugs “has not hurt our patients or our practice in the least. It gives us extra time to focus on patient care.”

Two physicians note the additional conflict of direct-to-consumer marketing.

Discussants argue for the benefit of providing samples to needy patients, “If you do not see a rep you do not get samples,” and learning from the reps, “I appreciate the opportunity to learn about the latest innovations that occur regarding medical care.”

Adam Goldstein decries the educational value of pharmaceutical reps, saying that the relationship “comes down to 1 of 2 things: either a plea for samples or a plea for food.” In an interview for US News & World Report, Dr. Goldstein reflects that pharmaceutical-sponsored meals “are part of our culture.”

My own analysis of the discussion is that Dr. Brody’s appraisal hits hard because it not only documents the moral argument but makes the practical case as well. The practical case is hard for family physicians to ignore, because we think of ourselves as pragmatists focused on what is best for our patients. Brody shows us that giving time and taking (skewed) information and (expensive) samples is neither practical nor in our patients’ interest.

As family physicians, we prescribe abstinence for our addicted patients, but offer cutting back as an option for those who are not ready to abstain. The first step should be to recognize the ignoble nature of our dependency and the insidious way in which we became addicted—typically through professional socialization during training and having the best intentions for our patients as practicing clinicians. We should try the experiment of cutting back or abstaining and explore other options for meeting our patients’ needs for affordable drugs, as well as our own needs to keep up with new knowledge. Brody’s analysis gives us good reason to believe that the experience of Drs. Mitchell and Fior will be our experience—that patients and our professionalism will benefit from the experiment. If we can break this addiction as individuals, we will gain the moral authority to ask our professional organizations to do the same.

DEPRESSION MANAGEMENT IN PRIMARY CARE

The cluster of 6 studies of depression and the related editorial provided a stimulus for responses addressing the following:

- Community participatory research as a fundamental approach to primary care inquiry
- Integrated care management
- Tailored, individualized, personalized care that empowers patients
I interpret this discussion as a cry for reduction in the fragmentation of care. Those on the front lines see fragmentation as a major cause of increased costs. This fragmentation lowers the effectiveness of diagnosis and treatment of depression and reduces the effectiveness of health care in general. Both researchers and clinicians see the potential of integration of care as a powerful way of enabling people to get on with their lives to the best extent possible, given chronic somatic and mental illness.

**OTHER STIMULUS AND RESPONSE**

Studies from the last issue of the Annals stimulated readers and shaped their thinking and responses. These studies "undermine the notion that there is a perceived ethical conflict between commitment to the well-being of the individual patient, and a concern for distributive justice and the health care needs of the entire society. They also "raise the intriguing question of how much lower the criteria will become for the diagnosis of 'diabetes' and how far ahead we should be thinking." Studies from the November/December 2004 issue of the Annals stimulated further responses that many are awaiting the results of the national demonstration project for the New Model of family medicine proposed by the Future of Family Medicine Project and financially modeled in the recent supplement. Writers also expressed frustration from both patients and physicians with overburdened access systems that result in no-shows.

The revisiting of the biopsychosocial model continues to resonate. "[M]oving from objective detachment to reflective participant could serve as a galvanizing sound-bite for what is required to move into high performance primary care. We all, patients and physicians alike, so desperately need a time and place where we can consult, 'mind-fully,' and we physicians need a workload and practice systems that will permit us to be prepared, available, attentive—indeed 'attending physicians.'"

Please join these and other writers in adding your insights at http://www.AnnFamMed.org. Click on “discussion of articles” or follow the links for the comments or the article on which you wish to comment.

**References**

1. Brody H. The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med. 2005;3:82-85.
2. Bettigole CA. The costs of a free lunch [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1558, 3 February 2005.
3. Hoffman JR. Meeting with the drug reps – why we shouldn’t do it [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1549, 2 February 2005.
4. Kelly MJ. Time management [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1539, 31 January 2005.
5. Rafool F. Re: pharmaceutical rep addiction [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1526, 29 January 2005.
6. Deng JY. Other sides of the issue – a resident’s comments [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1593, 14 February 2005.
7. Grief SN. Re: the company we keep [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1551, 2 February 2005.
8. Zweifler JA. Physicians and pharmaceutical representatives: too close for comfort [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1493, 28 January 2005.
9. Frey JJ. Sweeping off our own back porch [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1568, 7 February 2005.
10. Scott JC. Pharmaceutical rep addiction [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1479, 28 January 2005.
11. Mitchell DL. Response about drug reps [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1589, 14 February 2005.
12. Fink TW. What about direct to consumer (DTC) advertising [eletter]? http://www.annfammed.org/cgi/eletters/3/1/82#1537, 30 January 2005.
13. Hager JR. Advertising prescription drugs [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1531, 29 January 2005.
14. Goldstein AO. The ethics of food [eletter]. http://www.annfammed.org/cgi/eletters/3/1/82#1500, 29 January 2005.
15. Brink S. Wooling doctors: Say no to drug reps. Health Watch. February 14, 2005:62.
16. Stephens GG. The intellectual basis of family practice. In: The Intellectual Basis of Family Practice. Tucson, Ariz: Winter Publishing Co; Inc, 1982.
17. Rost K, Pyne JM, Dickinson LM, Elliott CE, deGruy F. The cost effectiveness of enhancing primary care depression management on an ongoing basis. Ann Fam Med. 2005;3:7-14.
18. Dickinson JM, Rost K, Nutter PA, Elliott CE, Keeley RD, Pincus H. Care manager for major depression in primary care: costs of outpatient care over two years comparing patients with physical versus psychological symptoms. Ann Fam Med. 2005;3:15-22.
19. Aikens JE, Nease DE, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of beliefs about medication. Ann Fam Med. 2005;3:23-30.
20. Baik S, Bowers BJ, Oakley LD, Susman JL. The recognition of depression: the primary care provider’s perspective. Ann Fam Med. 2005;3:31-37.
21. Van Voorhees BW, Fogel J, Houston TK, Cooper LA, Nae-Yuh W. Beliefs and attitudes associated with the intention to not accept the diagnosis of depression among young adults. Ann Fam Med. 2005;3:38-46.
22. Chene R, Garcia L, Goldstrom M, Pino M, Roach D, Thunderchief W, Waltzkin H. Mental health research in primary care: mandates from a community advisory board. Ann Fam Med. 2005;3:70-72.
23. deGruy F. Depression care: progress and prospects. Ann Fam Med. 2005;3:3-3-6.
24. Meyers DS. CBPR and PBRNs: methodologies for exploring primary [eletter]. http://www.annfammed.org/cgi/eletters/3/1/70#1610, 23 February 2005.
25. Macaulay AC. Recommended reading in community based participatory research [eletter]. http://www.annfammed.org/cgi/eletters/3/1/70#1597, 21 February 2005.
26. Herbert CP. Essential learning for community-based researchers [eletter]. http://www.annfammed.org/cgi/eletters/3/1/70#1547, 2 February 2005.
27. Smith JL. Can single-disease care managers be ‘faithful with much’? [eletter]. http://www.annfammed.org/cgi/eletters/3/1/3#1562, 5 February 2005.
28. Schwenk TL. Depression care is a New Model prototype [eletter]. http://www.annfammed.org/cgi/eletters/3/1/3#1464, 26 January 2005.
29. Bachman JA. What’s good for the patient is good for the business case [eletter]. http://www.annfammed.org/cgi/eletters/3/1/7#1566, 7 February 2005.
30. Rost K, et al. The unavoidable constraints of delivering improved depression care [eletter]. http://www.annfammed.org/cgi/eletters/3/1/7#1503, 29 January 2005.
31. Schulberg HC, et al. Multiple paths to diagnosing depression [eletter]. http://www.annfammed.org/cgi/eletters/3/1/31#1583, 11 February 2005.
32. Lin EHB. Commentary on beliefs and attitudes associated with the intention to not accept the diagnosis of depression among young adults [eletter]. http://www.annfammed.org/cgi/eletters/3/1/38#1468, 26 January 2005.
33. Dickinson LM. One size does not necessarily fit all [eletter]. http://www.annfammed.org/cgi/eletters/3/1/3#1466, 26 January 2005.
34. Steiner JF. Adherence decisions and disease management [eletter]. http://www.annfammed.org/cgi/eletters/3/1/23#1440, 26 January 2005.
35. Dowrick C. Is underrecognition of depression really a problem [eletter]? http://www.annfammed.org/cgi/eletters/3/1/31#1587, 14 February 2005.
36. Fogel J. Detecting and treating depression in primary care settings [eletter]. http://www.annfammed.org/cgi/eletters/3/1/31#1453, 26 January 2005.
37. Spurling MC, Vinson DC, Beach M, et al. Physician conceptions of responsibility to individual patients and distributive justice in healthcare. Ann Fam Med. 2005;3:53-59.
38. Brody H. Individual patients vs societal responsibility [eletter]. http://www.annfammed.org/cgi/eletters/3/1/3#1460, 26 January 2005.
39. Koopman RJ, Mainous AG, Diaz VA, Geesey ME. Changes in age at diagnosis of type 2 diabetes in the United States, 1988-2000. Ann Fam Med. 2005;3:60-63.
40. Smith K. Re: the age of diabetes [eletter]. http://www.annfammed.org/cgi/eletters/3/1/60#1581, 11 February 2005.
41. Task Force 1 Writing Group. Task Force 1. Report of the task force on patient expectations, core values, reintegration, and the new model of family medicine. Ann Fam Med. 2004;2:S33-S50.
42. Spann SJ, for the members of Task Force 6 and The Executive Editorial Team. Report on financing the new model of family medicine. Ann Fam Med. 2004;2:S1-S21.
43. Spann SJ, et al. Productivity and malpractice [eletter]. http://www.annfammed.org/cgi/eletters/2/suppl_3/s1#1577, 9 February 2005.
44. Jamison JF. USA/Mexico border no shows in pediatrics [eletter]. http://www.annfammed.org/cgi/eletters/2/6/541#1543, 2 February 2005.
45. Anonymous. Why they don’t show up [eletter]. http://www.annfammed.org/cgi/eletters/2/6/541#1443, 29 January 2005.
46. Bately NJ. Open access scheduling not equal to longer waiting room time [eletter]. http://www.annfammed.org/cgi/eletters/2/6/541#1472, 28 January 2005.
47. Johnson SL. Reverse no show [eletter]. http://www.annfammed.org/cgi/eletters/2/6/541#1445, 26 January 2005.
48. Menard EH. Timeliness and respect [eletter]. http://www.annfammed.org/cgi/eletters/2/6/541#1421, 5 January 2005.
49. Blicher AP. Disturbing preconceptions [eletter]. http://www.annfammed.org/cgi/eletters/2/6/546#1572, 8 February 2005.
50. Green LA. A sense of imminent progress [eletter]. http://www.annfammed.org/cgi/eletters/2/6/576#1411, 2 January 2005.